Baseline and end-point (last visit) SMMSE and Qmci scores
| N | Baseline age, mean (±SD) | Gender (male, %) | Duration of follow-up in months, median (Q3–Q1) | Baseline score, median (Q3−Q1) | End-point score, median (Q3–Q1) | ||
|---|---|---|---|---|---|---|---|
| SMMSE | CACE-I | 83 | 77.3 (±6.6) | 53 | 17 (34–7) | 22 (25–19) | 20 (25–14) |
| NoCACE-I | 270 | 77.1 (±7.6) | 49.3 | 18 (31–9) | 23 (26–19) | 20 (25–13) | |
| NewCACE-I | 30 | 77.3 (±8.2) | 50 | 6 (7–4) | 23 (27–18) | 24 (27–19) | |
| Qmci | CACE-I | 41 | 78.9 (±6.1) | 56.1 | 16 (31–7) | 36 (44–23) | 29 (49–15) |
| NoCACE-I | 114 | 78.0 (±7.6) | 49.1 | 11 (24–6) | 38 (47–27) | 32 (45–17) | |
CACE-I, patients currently receiving ACE inhibitors; NewCACE-I, patients who were newly started on CACE-Is; NoCACE-I, patients who are not currently prescribed CACE-Is; Qmci, Quick Mild Cognitive Impairment; SMMSE, Standardised Mini-Mental State Examination.